annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
1183533981 | rs2290732 | rs2290732 | GABRA1 | AG | 3 | Efficacy | carbamazepine | Epilepsy | Patients with the AG genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine. | https://www.clinpgx.org/clinicalAnnotation/1183533981 |
1183533981 | rs2290732 | rs2290732 | GABRA1 | GG | 3 | Efficacy | carbamazepine | Epilepsy | Patients with the GG genotype and epilepsy may have decreased retention rates when treated with carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine. | https://www.clinpgx.org/clinicalAnnotation/1183533981 |
1183533986 | rs2246709 | rs2246709 | CYP3A4 | AA | 4 | Efficacy | amlodipine | Hypertension | Patients with the AA genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm H... | https://www.clinpgx.org/clinicalAnnotation/1183533986 |
1183533986 | rs2246709 | rs2246709 | CYP3A4 | AG | 4 | Efficacy | amlodipine | Hypertension | Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or... | https://www.clinpgx.org/clinicalAnnotation/1183533986 |
1183533986 | rs2246709 | rs2246709 | CYP3A4 | GG | 4 | Efficacy | amlodipine | Hypertension | Patients with the GG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or... | https://www.clinpgx.org/clinicalAnnotation/1183533986 |
1183543916 | rs2241883 | rs2241883 | FABP1 | CC | 4 | Efficacy | fenofibrate | Hypertriglyceridemia | Patients with the CC genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were s... | https://www.clinpgx.org/clinicalAnnotation/1183543916 |
1183543916 | rs2241883 | rs2241883 | FABP1 | CT | 4 | Efficacy | fenofibrate | Hypertriglyceridemia | Patients with the CT genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were s... | https://www.clinpgx.org/clinicalAnnotation/1183543916 |
1183543916 | rs2241883 | rs2241883 | FABP1 | TT | 4 | Efficacy | fenofibrate | Hypertriglyceridemia | Patients with the TT genotype and hypertriglyceridemia may have a decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the CC or CT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia w... | https://www.clinpgx.org/clinicalAnnotation/1183543916 |
1183545767 | rs964184 | rs964184 | APOA1 | CC | 3 | Efficacy | fenofibrate | Hypertriglyceridemia | Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate. | https://www.clinpgx.org/clinicalAnnotation/1183545767 |
1183545767 | rs964184 | rs964184 | APOA1 | CG | 3 | Efficacy | fenofibrate | Hypertriglyceridemia | Patients with the CG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype or a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence respo... | https://www.clinpgx.org/clinicalAnnotation/1183545767 |
1183545767 | rs964184 | rs964184 | APOA1 | GG | 3 | Efficacy | fenofibrate | Hypertriglyceridemia | Patients with the GG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate. | https://www.clinpgx.org/clinicalAnnotation/1183545767 |
1183547855 | rs8330 | rs8330 | UGT1A | CC | 3 | Other | acetaminophen | null | Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins. | https://www.clinpgx.org/clinicalAnnotation/1183547855 |
1183547855 | rs8330 | rs8330 | UGT1A | CG | 3 | Other | acetaminophen | null | Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins. | https://www.clinpgx.org/clinicalAnnotation/1183547855 |
1183547855 | rs8330 | rs8330 | UGT1A | GG | 3 | Other | acetaminophen | null | Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins. | https://www.clinpgx.org/clinicalAnnotation/1183547855 |
1183549413 | rs8330 | rs8330 | UGT1A;UGT1A9 | CC | 3 | Toxicity | acetaminophen | Liver Failure, Acute | Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose. | https://www.clinpgx.org/clinicalAnnotation/1183549413 |
1183549413 | rs8330 | rs8330 | UGT1A;UGT1A9 | CG | 3 | Toxicity | acetaminophen | Liver Failure, Acute | Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose. | https://www.clinpgx.org/clinicalAnnotation/1183549413 |
1183549413 | rs8330 | rs8330 | UGT1A;UGT1A9 | GG | 3 | Toxicity | acetaminophen | Liver Failure, Acute | Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose. | https://www.clinpgx.org/clinicalAnnotation/1183549413 |
1183554425 | rs7921977 | rs7921977 | CASP7 | CC | 3 | Efficacy | docetaxel;gemcitabine;paclitaxel;Platinum compounds;vinorelbine | Non-Small Cell Lung Carcinoma | Patients with the CC genotype and non-small cell lung cancer show no significant differences in progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. However, patients with the CT ge... | https://www.clinpgx.org/clinicalAnnotation/1183554425 |
1183554425 | rs7921977 | rs7921977 | CASP7 | CT | 3 | Efficacy | docetaxel;gemcitabine;paclitaxel;Platinum compounds;vinorelbine | Non-Small Cell Lung Carcinoma | Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influe... | https://www.clinpgx.org/clinicalAnnotation/1183554425 |
1183554425 | rs7921977 | rs7921977 | CASP7 | TT | 3 | Efficacy | docetaxel;gemcitabine;paclitaxel;Platinum compounds;vinorelbine | Non-Small Cell Lung Carcinoma | Patients with the TT genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CT genotype. Other genetic and clinical factors may also infl... | https://www.clinpgx.org/clinicalAnnotation/1183554425 |
1183556309 | rs7787082 | rs7787082 | ABCB1 | AA | 3 | Efficacy | clozapine | Schizophrenia | Patients with the AA genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine. | https://www.clinpgx.org/clinicalAnnotation/1183556309 |
1183556309 | rs7787082 | rs7787082 | ABCB1 | AG | 3 | Efficacy | clozapine | Schizophrenia | Patients with the AG genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype or a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to cloz... | https://www.clinpgx.org/clinicalAnnotation/1183556309 |
1183556309 | rs7787082 | rs7787082 | ABCB1 | GG | 3 | Efficacy | clozapine | Schizophrenia | Patients with the GG genotype and schizophrenia may have a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine. | https://www.clinpgx.org/clinicalAnnotation/1183556309 |
1183556815 | rs776746 | rs776746 | CYP3A5 | CC | 3 | Other | ondansetron | null | Patients with the CC genotype may have decreased metabolism of ondansetron as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron. | https://www.clinpgx.org/clinicalAnnotation/1183556815 |
1183556815 | rs776746 | rs776746 | CYP3A5 | CT | 3 | Other | ondansetron | null | Patients with the CT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron. | https://www.clinpgx.org/clinicalAnnotation/1183556815 |
1183556815 | rs776746 | rs776746 | CYP3A5 | TT | 3 | Other | ondansetron | null | Patients with the TT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron. | https://www.clinpgx.org/clinicalAnnotation/1183556815 |
1183562698 | rs62205366 | rs62205366 | GNAS | CC | 3 | Efficacy | dobutamine | null | Healthy males with the CC genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine. | https://www.clinpgx.org/clinicalAnnotation/1183562698 |
1183562698 | rs62205366 | rs62205366 | GNAS | CT | 3 | Efficacy | dobutamine | null | Healthy males with the CT genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine. | https://www.clinpgx.org/clinicalAnnotation/1183562698 |
1183562698 | rs62205366 | rs62205366 | GNAS | TT | 3 | Efficacy | dobutamine | null | Healthy males with the TT genotype may have a decreased response when given dobutamine as compared to healthy males with the CC or CT genotype. Other genetic and clinical factors may also influence response to dobutamine. | https://www.clinpgx.org/clinicalAnnotation/1183562698 |
1183563324 | rs5443 | rs5443 | GNB3 | CC | 3 | Efficacy | bumetanide;furosemide;torasemide | null | Healthy males with the CC genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide. | https://www.clinpgx.org/clinicalAnnotation/1183563324 |
1183563324 | rs5443 | rs5443 | GNB3 | CT | 3 | Efficacy | bumetanide;furosemide;torasemide | null | Healthy males with the CT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical fac... | https://www.clinpgx.org/clinicalAnnotation/1183563324 |
1183563324 | rs5443 | rs5443 | GNB3 | TT | 3 | Efficacy | bumetanide;furosemide;torasemide | null | Healthy males with the TT genotype have have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide. | https://www.clinpgx.org/clinicalAnnotation/1183563324 |
1183564259 | rs5370 | rs5370 | EDN1 | GG | 3 | Efficacy | atenolol;irbesartan | Essential hypertension | Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systol... | https://www.clinpgx.org/clinicalAnnotation/1183564259 |
1183564259 | rs5370 | rs5370 | EDN1 | GT | 3 | Efficacy | atenolol;irbesartan | Essential hypertension | Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systol... | https://www.clinpgx.org/clinicalAnnotation/1183564259 |
1183564259 | rs5370 | rs5370 | EDN1 | TT | 3 | Efficacy | atenolol;irbesartan | Essential hypertension | No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, ... | https://www.clinpgx.org/clinicalAnnotation/1183564259 |
1183564845 | rs5186 | rs5186 | AGTR1 | AA | 3 | Efficacy | candesartan | Heart Failure | Patients with the AA genotype and heart failure may have an increased response when treated with candesartan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence response to candesartan. | https://www.clinpgx.org/clinicalAnnotation/1183564845 |
1183564845 | rs5186 | rs5186 | AGTR1 | AC | 3 | Efficacy | candesartan | Heart Failure | Patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan. | https://www.clinpgx.org/clinicalAnnotation/1183564845 |
1183564845 | rs5186 | rs5186 | AGTR1 | CC | 3 | Efficacy | candesartan | Heart Failure | No patients with the CC genotype were present in the study analysis. However, patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan. | https://www.clinpgx.org/clinicalAnnotation/1183564845 |
1183574175 | rs2952768 | rs2952768 | null | CC | 3 | Efficacy | opioids | Pain, Postoperative | Patients with the rs2952768 CC genotype may have a decreased analgesic response to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to opioids. | https://www.clinpgx.org/clinicalAnnotation/1183574175 |
1183574175 | rs2952768 | rs2952768 | null | CT | 3 | Efficacy | opioids | Pain, Postoperative | Patients with the rs2952768 CT genotype may have an increased analgesic response to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to opioids. | https://www.clinpgx.org/clinicalAnnotation/1183574175 |
1183574175 | rs2952768 | rs2952768 | null | TT | 3 | Efficacy | opioids | Pain, Postoperative | Patients with the rs2952768 TT genotype may have an increased analgesic response to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to opioids. | https://www.clinpgx.org/clinicalAnnotation/1183574175 |
1183589777 | rs4961 | rs4961 | ADD1 | GG | 3 | Efficacy | bumetanide;furosemide;torasemide | null | Healthy males with the GG genotype may have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide. | https://www.clinpgx.org/clinicalAnnotation/1183589777 |
1183589777 | rs4961 | rs4961 | ADD1 | GT | 3 | Efficacy | bumetanide;furosemide;torasemide | null | Healthy males with the GT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical fac... | https://www.clinpgx.org/clinicalAnnotation/1183589777 |
1183589777 | rs4961 | rs4961 | ADD1 | TT | 3 | Efficacy | bumetanide;furosemide;torasemide | null | Healthy males with the TT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide. | https://www.clinpgx.org/clinicalAnnotation/1183589777 |
1183590959 | rs495794 | rs495794 | SRP19 | AA | 3 | Efficacy | citalopram;fluoxetine;paroxetine;sertraline | Major Depressive Disorder | Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline. | https://www.clinpgx.org/clinicalAnnotation/1183590959 |
1183590959 | rs495794 | rs495794 | SRP19 | AG | 3 | Efficacy | citalopram;fluoxetine;paroxetine;sertraline | Major Depressive Disorder | Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients ... | https://www.clinpgx.org/clinicalAnnotation/1183590959 |
1183590959 | rs495794 | rs495794 | SRP19 | GG | 3 | Efficacy | citalopram;fluoxetine;paroxetine;sertraline | Major Depressive Disorder | Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline. | https://www.clinpgx.org/clinicalAnnotation/1183590959 |
1183592332 | rs4353229 | rs4353229 | CASP7 | CC | 3 | Efficacy | docetaxel;gemcitabine;paclitaxel;Platinum compounds;vinorelbine | Non-Small Cell Lung Carcinoma | Patients with the CC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall s... | https://www.clinpgx.org/clinicalAnnotation/1183592332 |
1183592332 | rs4353229 | rs4353229 | CASP7 | CT | 3 | Efficacy | docetaxel;gemcitabine;paclitaxel;Platinum compounds;vinorelbine | Non-Small Cell Lung Carcinoma | Patients with the CT genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall s... | https://www.clinpgx.org/clinicalAnnotation/1183592332 |
1183592332 | rs4353229 | rs4353229 | CASP7 | TT | 3 | Efficacy | docetaxel;gemcitabine;paclitaxel;Platinum compounds;vinorelbine | Non-Small Cell Lung Carcinoma | Patients with the TT genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC or CT genotype. No significant association between this SNP and ove... | https://www.clinpgx.org/clinicalAnnotation/1183592332 |
1183594148 | rs4291 | rs4291 | ACE | AA | 3 | Efficacy | amlodipine;chlorthalidone;lisinopril | Hypertension | Patients with the AA genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels. | https://www.clinpgx.org/clinicalAnnotation/1183594148 |
1183594148 | rs4291 | rs4291 | ACE | AT | 3 | Efficacy | amlodipine;chlorthalidone;lisinopril | Hypertension | Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels. | https://www.clinpgx.org/clinicalAnnotation/1183594148 |
1183594148 | rs4291 | rs4291 | ACE | TT | 3 | Efficacy | amlodipine;chlorthalidone;lisinopril | Hypertension | Patients with the TT genotype and hypertension may have increased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fasting glucose levels. | https://www.clinpgx.org/clinicalAnnotation/1183594148 |
1183601914 | rs3091244 | rs3091244 | CRP | AA | 3 | Efficacy | fenofibrate | Metabolic Syndrome | Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate. | https://www.clinpgx.org/clinicalAnnotation/1183601914 |
1183601914 | rs3091244 | rs3091244 | CRP | AG | 3 | Efficacy | fenofibrate | Metabolic Syndrome | Patients with the AG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate. | https://www.clinpgx.org/clinicalAnnotation/1183601914 |
1183601914 | rs3091244 | rs3091244 | CRP | AT | 3 | Efficacy | fenofibrate | Metabolic Syndrome | Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate. | https://www.clinpgx.org/clinicalAnnotation/1183601914 |
1183601914 | rs3091244 | rs3091244 | CRP | GG | 3 | Efficacy | fenofibrate | Metabolic Syndrome | Patients with the GG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate. | https://www.clinpgx.org/clinicalAnnotation/1183601914 |
1183601914 | rs3091244 | rs3091244 | CRP | GT | 3 | Efficacy | fenofibrate | Metabolic Syndrome | Patients with the GT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate. | https://www.clinpgx.org/clinicalAnnotation/1183601914 |
1183602560 | rs2742435 | rs2742435 | SACM1L | AA | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183602560 |
1183602560 | rs2742435 | rs2742435 | SACM1L | AG | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1183602560 |
1183602560 | rs2742435 | rs2742435 | SACM1L | GG | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183602560 |
1183602693 | rs2742423 | rs2742423 | SACM1L | AA | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183602693 |
1183602693 | rs2742423 | rs2742423 | SACM1L | AG | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1183602693 |
1183602693 | rs2742423 | rs2742423 | SACM1L | GG | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183602693 |
1183602849 | rs2742421 | rs2742421 | SACM1L | GG | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183602849 |
1183602849 | rs2742421 | rs2742421 | SACM1L | GT | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the GT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1183602849 |
1183602849 | rs2742421 | rs2742421 | SACM1L | TT | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183602849 |
1183603016 | rs2742417 | rs2742417 | SACM1L | CC | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183603016 |
1183603016 | rs2742417 | rs2742417 | SACM1L | CT | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1183603016 |
1183603016 | rs2742417 | rs2742417 | SACM1L | TT | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183603016 |
1183603158 | rs2742390 | rs2742390 | SACM1L | AA | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the AA genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183603158 |
1183603158 | rs2742390 | rs2742390 | SACM1L | AG | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1183603158 |
1183603158 | rs2742390 | rs2742390 | SACM1L | GG | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the GG genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183603158 |
1183603764 | rs2497538 | rs2497538 | HTR2C | AA | 3 | Toxicity | olanzapine | Weight gain | Patients with two X-chromosomes, the AA genotype, and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome t... | https://www.clinpgx.org/clinicalAnnotation/1183603764 |
1183603764 | rs2497538 | rs2497538 | HTR2C | AC | 3 | Toxicity | olanzapine | Weight gain | Patients with two X-chromosomes, the AC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype, or decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. O... | https://www.clinpgx.org/clinicalAnnotation/1183603764 |
1183603764 | rs2497538 | rs2497538 | HTR2C | CC | 3 | Toxicity | olanzapine | Weight gain | Patients with two X-chromosomes, the CC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome t... | https://www.clinpgx.org/clinicalAnnotation/1183603764 |
1183603970 | rs2440390 | rs2440390 | DRD2 | CC | 3 | Toxicity | olanzapine | Mental Disorders | Patients with the CC genotype and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain. | https://www.clinpgx.org/clinicalAnnotation/1183603970 |
1183603970 | rs2440390 | rs2440390 | DRD2 | CT | 3 | Toxicity | olanzapine | Mental Disorders | Patients with the CT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype, or decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight ga... | https://www.clinpgx.org/clinicalAnnotation/1183603970 |
1183603970 | rs2440390 | rs2440390 | DRD2 | TT | 3 | Toxicity | olanzapine | Mental Disorders | Patients with the TT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain. | https://www.clinpgx.org/clinicalAnnotation/1183603970 |
1183604439 | rs2251954 | rs2251954 | SACM1L | CC | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183604439 |
1183604439 | rs2251954 | rs2251954 | SACM1L | CT | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1183604439 |
1183604439 | rs2251954 | rs2251954 | SACM1L | TT | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183604439 |
1183604793 | rs2245705 | rs2245705 | SACM1L | CC | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183604793 |
1183604793 | rs2245705 | rs2245705 | SACM1L | CT | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/1183604793 |
1183604793 | rs2245705 | rs2245705 | SACM1L | TT | 3 | Toxicity | bupropion | Major Depressive Disorder | Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects. | https://www.clinpgx.org/clinicalAnnotation/1183604793 |
1183605282 | rs2239347 | rs2239347 | IL4R | AA | 3 | Efficacy | pitrakinra | Asthma | Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/1183605282 |
1183605282 | rs2239347 | rs2239347 | IL4R | AC | 3 | Efficacy | pitrakinra | Asthma | Patients with the AC genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/1183605282 |
1183605282 | rs2239347 | rs2239347 | IL4R | CC | 3 | Efficacy | pitrakinra | Asthma | Patients with the CC genotype and asthma may have a higher frequency of asthma exacerbationswhen treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/1183605282 |
1183605989 | rs2239128 | rs2239128 | CACNA1C | CC | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the CC genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. However, no significant association was seen in a subpopulation of ... | https://www.clinpgx.org/clinicalAnnotation/1183605989 |
1183605989 | rs2239128 | rs2239128 | CACNA1C | CT | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the C... | https://www.clinpgx.org/clinicalAnnotation/1183605989 |
1183605989 | rs2239128 | rs2239128 | CACNA1C | TT | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the TT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC genotype. However, no significant association was seen in a subpopulation of ... | https://www.clinpgx.org/clinicalAnnotation/1183605989 |
1183606395 | rs2239050 | rs2239050 | CACNA1C | CC | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the rs2239050 CC genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence blood pressure response. | https://www.clinpgx.org/clinicalAnnotation/1183606395 |
1183606395 | rs2239050 | rs2239050 | CACNA1C | CG | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the rs2239050 CG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence blood pressure response. | https://www.clinpgx.org/clinicalAnnotation/1183606395 |
1183606395 | rs2239050 | rs2239050 | CACNA1C | GG | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the rs2239050 GG genotype and hypertension may have improved blood pressure response when treated with calcium channel blockers as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence blood pressure response. | https://www.clinpgx.org/clinicalAnnotation/1183606395 |
1183606758 | rs2238032 | rs2238032 | CACNA1C | GG | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the GG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to c... | https://www.clinpgx.org/clinicalAnnotation/1183606758 |
1183606758 | rs2238032 | rs2238032 | CACNA1C | GT | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the GT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to c... | https://www.clinpgx.org/clinicalAnnotation/1183606758 |
1183606758 | rs2238032 | rs2238032 | CACNA1C | TT | 3 | Efficacy | Calcium channel blockers | Hypertension | Patients with the TT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence respons... | https://www.clinpgx.org/clinicalAnnotation/1183606758 |
1183607013 | rs2237895 | rs2237895 | KCNQ1 | AA | 3 | Efficacy | repaglinide | Diabetes Mellitus, Type 2 | Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide. | https://www.clinpgx.org/clinicalAnnotation/1183607013 |
1183607013 | rs2237895 | rs2237895 | KCNQ1 | AC | 3 | Efficacy | repaglinide | Diabetes Mellitus, Type 2 | Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide. | https://www.clinpgx.org/clinicalAnnotation/1183607013 |
1183607013 | rs2237895 | rs2237895 | KCNQ1 | CC | 3 | Efficacy | repaglinide | Diabetes Mellitus, Type 2 | Patients with the CC genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide. | https://www.clinpgx.org/clinicalAnnotation/1183607013 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.